profit from every $100 of sales.
$0$100
Fortress Biotech
$1.88-5.53% today
-24.5% in 1 year
1-year low $1.841-year high $4.38
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay $9.20 for every $1 of profit it makes in a year.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Fortress Biotech sold, what it kept, and what it did with the cash.
Sales went from $75.7 million in 2022 to $63.3 million in 2025, with $6.82 million of profit last year.
SalesProfit
Fortress Biotech vs. similar companies
Fortress Biotech grows the slowest of these 5 and is the cheapest for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Fortress Biotech | 9.2× · Cheap | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Fortress Biotech's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 76 | 85 | 58 | 63 | |
| 45 | 62 | 37 | 42 | |
| -204 | -139 | -111 | -70 | |
| -194 | -136 | -104 | -20 | |
| -87 | -61 | -46 | 7 | |
| -14.55 | -8.47 | -2.69 | -0.07 | |
| 59.4% | 72.9% | 63.8% | 66.9% | |
| -268.8% | -164.7% | -192.9% | -111.0% | |
| -114.3% | -71.7% | -79.8% | 10.8% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 294 | 168 | 144 | 186 |
| Cash | 178 | 81 | 57 | 79 |
| Total debt | 127 | 85 | 76 | 74 |
| Total liabilities | 244 | 166 | 146 | 123 |
| 42 | 23 | 23 | 50 | |
| 6 | 8 | 21 | 28 | |
| -94.9% | -104.4% | -87.2% | -15.8% | |
| -207.5% | -269.0% | -202.3% | 13.7% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -179 | -128 | -80 | -66 | |
| 3 | 8 | 15 | – | |
| -182 | -136 | -95 | -66 | |
| Dividends paid | 9 | 9 | 5 | 1 |
| 1 | 0 | 0 | 0 | |
| 23 | 17 | 33 | 29 |
Valuation
- 9.2×
- –
- –
- 1.3×
- 1.0×
- –
- –
- -104.9%
- 10.9%
- 0.0%
Profitability
- 66.9%
- -111.0%
- 10.8%
- -76.9%
- -16.2%
- -77.5%
- 161.3%
- 35.2%
- -22.0%
- 12.9%
Growth
- −5.8%
- –
- +30.9%
- –
- +67.6%
Financial health
- -0.3×
- 1.49
- 15.0%
- -2.9×
- 2.49
- 2.77
- 0.19
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 20%of 952
Bottom 3%of 884
Top 8%of 601
Bottom 10%of 886
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 14, 2026 | 2.82 | -0.22 | +1,381.8% |
| Mar 31, 2026 | -0.21 | 0.42 | −150.0% |
| Nov 14, 2025 | 0.11 | -0.43 | +125.6% |
| Aug 14, 2025 | -0.46 | -0.31 | −48.4% |
| May 21, 2025 | -1.03 | -0.44 | −134.1% |
| Mar 27, 2025 | -0.53 | -0.79 | +32.9% |
| Nov 14, 2024 | -0.76 | -0.27 | −181.5% |
| Aug 13, 2024 | -0.73 | -1.32 | +44.7% |
News
Apple's $320 Stock Faces Huawei's 68% Foldable FortressYahoo Finance · Sep 7, 2026The newest story we have is from Sep 7, 2026.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
50No pass
Benjamin Graham
65Pass
Philip Fisher
48No pass
Peter Lynch
32No pass
Joel Greenblatt
24No pass
Charlie Munger
36No pass
Terry Smith
39No pass
Questions about Fortress Biotech
Is Fortress Biotech a good stock to buy?
A solid business, and the price looks low. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Fortress Biotech AI analysis
What does Fortress Biotech do?
Fortress Biotech, Inc., together with its subsidiaries, operates as a biopharmaceutical company in the United States and internationally. It is in Biotechnology.
Does Fortress Biotech pay a dividend?
Yes. In 2025 it paid out $664,000 in dividends.
Is Fortress Biotech stock halal?
No. Fortress Biotech does not pass our halal screen: its debt is 119% of its market value, at or above the 33% limit. How we check
How has Fortress Biotech stock done over the past year?
Down 24.5% over the past twelve months, to $1.88. It traded between $1.84 and $4.38 and is 57.1% below its high.
Who are Fortress Biotech's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Fortress Biotech's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.